Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
TG Therapeutics, Inc.
TGTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $8.2B
$51.78
▼ -3.25%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$25.28 - $57.38
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 47.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Glycoengineered monoclonal antibody technology with enhanced efficacy
- Dual-mechanism oral inhibitors targeting PI3K-delta and CK1-epsilon pathways
- Strategic partnerships with established pharmaceutical and biotech companies
- Selective BTK inhibitor candidate with improved safety profile versus competitors
Bear Case
2 risks
- Above-average volatility (beta 1.7).
- Growth premium of 1.4x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Moderate growth ahead
Regulatory approvals and commercialization of Ublituximab and Umbralisib
Value
Growth premium of 1.4x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Hot
+59.6% over 3m
Quality
Excellent
High-growth business (81% revenue growth, 83% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying TGTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 6, 2026
Reported EPS of $0.14 vs $0.23 consensus (-39.1% surprise). Revenue of $204.9M vs $200.3M expected (+2.3%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-39.1%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+146%
+90%
+92%
+93%
+78%
+70%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$73.5M
$83.9M
$108.2M
$120.9M
$141.1M
$161.7M
$192.6M
$204.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
9.7%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
$70.00
▲ +35.2% vs $51.78
Latest: HC Wainwright · May 27, 2026
1 analyst covering